New Humira Biosimilar, Abrilada, Receives FDA Approval
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The RheumatoidArthritis.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- FDA Approves Pfizer’s Biosimilar, Abrilada (adalimumab-afzb) for multiple inflammatory conditions. Pfizer Inc. Available at: https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_pfizer_s_biosimilar_abrilada_adalimumab_afzb_for_multiple_inflammatory_conditions. Accessed 11/19/2019.